At a glance
ClinicalIndex Comparison RecordN/ACompleted· 391 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot.
In Brief
An observational study for Genital Endometriosis. Completed, enrolled 391 participants across 28 sites.
Detailed Summary
The purpose of this study is to assess rates of administration of add-back therapy in patients with endometriosis in the Russian Federation, during a 6-month course of gonadoliberin agonist leuprorelin 3.75 mg.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Endometriosis
CountriesRussia
CollaboratorsAlmedis
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedFeb 11, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.4 years ago